

M22 - OLANZAPINE

Version date: 2025-02-12 Effective date: 2025-04-30 (07:00)

INDICATIONS

• Known or suspected methamphetamine psychosis

WARNINGS

ABSOLUTE CONTRAINDICATIONS:

- Hypersensitivity to olanzapine
- Uncooperative patient
- Hypotension
- Seizure or acute neurological deficit
- Chest pain or dyspnea suspicious for acute cardiac syndrome (ACS)

USE WITH CAUTION:

- History of extrapyramidal side effects
- History of neuroleptic malignant syndrome

ADMINISTRATION	
ORAL	PCP / ICP / ACP
ADULTS / ADOLESCENTS: • Administer 10 mg once	

NOTES

1. Patients who have taken methamphetamine may rapidly develop extreme paranoia and demonstrate violent behavior with enhanced physical strength. After the onset of psychosis, forced medication administration may be difficult. Administration of olanzapine while the patient is cooperative may lessen the severity of psychotic symptoms.

LINKS

E02 - Agitation

APPROVED BY	
Bytherel	ffment.
Provincial Medical Director	Associate Provincial Medical Director

VERSION CHANGES (refer to X08 for change tracking)

- Addition of advanced work scope
- Revised contraindications & cautions